N/A
Completed N=11
Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies
Source: ClinicalTrials.gov NCT04332419 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcomePrimary: Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues — 16.9 percent difference
Summary
The purpose of this study is to compare the results of positron emission tomography/computer tomography (PET/CT) to positron emission tomography/magnetic resonance imaging (PET/MRI) to help determine any added advantage of one over the other in relation to a tumor which might assist in further management plans.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues |
16.9 | — |
| SECONDARY RDC Between the Two Imaging Modalities in Background Liver Tissues |
25.8 | — |
Eligibility Criteria
Inclusion Criteria
- The patient has a liver malignancy and is scheduled for SIRT with Y-90; AND
- The patient is an adult, self-competent, and able to provide informed consent to participate in the study
Exclusion Criteria
- The patient loses competence, has a condition that questions their ability to provide informed consent independently (e.g. cannot communicate in English), or withdraws consent to participate within any time in the study period; OR
- The patient is not eligible to undergo MRI due to the presence of metal devices or implants in their body; OR
- Both imaging modalities cannot take place within 6 hours after Y-90 RE; OR
- Both imaging modalities cannot take place within 1 hour apart from each other
Data sourced from ClinicalTrials.gov (NCT04332419). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.